{
    "code": "60001143",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001143",
    "time": "2024-01-11 20:43:24",
    "許可證字號": "衛部菌疫輸字第001143號",
    "註銷狀態": "已註銷",
    "註銷日期": "112\/12\/26",
    "註銷理由": "證別變更",
    "製造許可登錄編號": "",
    "有效日期": "114\/11\/09",
    "發證\/登錄日期": "109\/11\/09",
    "許可證\/登錄種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA06000114306",
    "中文品名": "櫻普立 皮下注射劑120毫克",
    "英文品名": "ENSPRYNG 120 mg for SC Injection",
    "適應症": "適用於治療水通道蛋白4自體抗體陽性[anti-aquaporin-4 (AQP4) antibody positive]的泛視神經脊髓炎(Neuromyelitis optica spectrum disorder, NMOSD)之成人及12歲以上青少年病人。",
    "劑型": "27D注射液劑",
    "包裝": "1毫升預充塑膠針筒裝，一百支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "基因工程產品_新成分;",
    "監視期限": "114\/11\/09",
    "主成分略述": "satralizumab",
    "限制項目": "02輸　入 1D須執行風險管理計畫 5F免除銜接性試驗",
    "申請商名稱": "台灣中外製藥股份有限公司",
    "申請商地址": "台北市松山區敦化北路260號3樓",
    "主製造廠": [
        {
            "製造廠名稱": "UTSUNOMIYA PLANT OF CHUGAI PHARMA MANUFACTURING CO., LTD.",
            "製造廠廠址": "16-3 KIYOHARA KOGYODANCHI, UTSUNOMIYA-CITY, TOCHIGI, JAPAN",
            "製造廠公司地址": "5-1 UKIMA 5-CHOME,KITA-KU,TOKYO,JAPAN",
            "製造廠國別": "JAPAN",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "UKIMA PLANT OF CHUGAI PHARMA MANUFACTURING CO., LTD.",
            "製造廠廠址": "5-1, UKIMA 5-CHOME, KITA-KU, TOKYO JAPAN",
            "製造廠公司地址": "",
            "製造廠國別": "JAPAN",
            "製程": "原料藥製造廠"
        },
        {
            "製造廠名稱": "BUSHU PHARMACEUTICALS LTD.",
            "製造廠廠址": "1 TAKENO, KAWAGOE-SHI, SAITAMA, 350-0801, JAPAN",
            "製造廠公司地址": "",
            "製造廠國別": "JAPAN",
            "製程": "次包裝廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013008400",
            "成分名稱": "satralizumab",
            "含量描述": "",
            "含量": "120.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Enspryng TPI drafted approved V3 (clean)_20220209-111-03-30.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001143&Seq=004&Type=9"
        },
        {
            "title": "1123-Enspryng 櫻普立皮下注射劑-tray label-109-12-08.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001143&Seq=004&Type=8"
        },
        {
            "title": "1123-Enspryng 櫻普立皮下注射劑-carton(outside)-109-12-08.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001143&Seq=003&Type=8"
        },
        {
            "title": "1023-Enspryng 櫻普立皮下注射劑-label-109-12-08.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001143&Seq=002&Type=8"
        },
        {
            "title": "0717-Enspryng 櫻普立皮下注射劑-carton(inside)-109-12-08.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001143&Seq=001&Type=8"
        }
    ]
}